|
|
Blood, 1 October 2006, Vol. 108, No. 7, pp. 2392-2398.
Prepublished online as a Blood First Edition Paper on June 15, 2006; DOI 10.1182/blood-2006-03-007468.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells
Kumudha Balakrishnan,
Ramadevi Nimmanapalli,
Farhad Ravandi,
Michael J. Keating, and
Varsha Gandhi
From the Departments of Experimental Therapeutics and Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
Purine nucleoside phosphorylase (PNP) deficiency in humans results in T lymphocytopenia. Forodesine, a potent inhibitor of PNP, was designed based on the transition-state structure stabilized by the enzyme. Previous studies established that forodesine in the presence of deoxyguanosine (dGuo) inhibits the proliferation of T lymphocytes. A phase 1 clinical trial of forodesine in T-cell malignancies demonstrated significant antileukemic activity with an increase in intracellular dGuo triphosphate (dGTP). High accumulation of dGTP in T cells may be dependent on the levels of deoxynucleoside kinases. Because B-cell chronic lymphocytic leukemia (B-CLL) cells have high activity of deoxycytidine kinase (dCK), we hypothesized that these lymphocytes would respond to forodesine. This postulate was tested in primary lymphocytes during in vitro investigations. Lymphocytes from 12 patients with CLL were incubated with forodesine and dGuo. These CLL cells showed a wide variation in the accumulation of intracellular dGTP without any effect on other deoxynucleotides. This was associated with DNA damage-induced p53 stabilization, phosphorylation of p53 at Ser15, and activation of p21. The dGTP accumulation was related to induction of apoptosis measured by caspase activation, changes in mitochondrial membrane potential, and PARP cleavage. Based on these data, a phase 2 clinical trial of forodesine has been initiated for CLL patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Alonso, M. Lopez-Guerra, R. Upshaw, S. Bantia, C. Smal, F. Bontemps, C. Manz, T. Mehrling, N. Villamor, E. Campo, et al.
Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM
Blood,
August 20, 2009;
114(8):
1563 - 1575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-Y. Tsai, A. S. Ray, D. B. Tumas, M. J. Keating, H. Reiser, and W. Plunkett
Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219
Clin. Cancer Res.,
June 1, 2009;
15(11):
3760 - 3769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Balakrishnan, J. A. Burger, W. G. Wierda, and V. Gandhi
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance
Blood,
January 1, 2009;
113(1):
149 - 153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Gandhi, C. Tam, S. O'Brien, R. C. Jewell, C. O. Rodriguez Jr, S. Lerner, W. Plunkett, and M. J. Keating
Phase I Trial of Nelarabine in Indolent Leukemias
J. Clin. Oncol.,
March 1, 2008;
26(7):
1098 - 1105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. L. Schramm
Enzymatic Transition State Theory and Transition State Analogue Design
J. Biol. Chem.,
September 28, 2007;
282(39):
28297 - 28300.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, R. M. Ricklis, K. Balakrishnan, J. Briel, J. Greer, S. D. Gore, B. D. Smith, M. A. McDevitt, H. Carraway, M. J. Levis, et al.
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias
Blood,
September 15, 2007;
110(6):
1762 - 1769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nimmanapalli, M.-A. Lyu, M. Du, M. J. Keating, M. G. Rosenblum, and V. Gandhi
The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells
Blood,
March 15, 2007;
109(6):
2557 - 2564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
